David Crosiers

List of Publications by Year
in descending order

37 papers	1,705 citations	394390 19 h-index	377849 34 g-index
39 all docs	39 docs citations	39 times ranked	3065 citing authors

#	Article	IF	Citations
1	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
2	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a caseâ€“control study. Lancet Neurology, The, 2011, 10, 898-908.	10.2	294
3	Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology, 2012, 79, 659-667.	1.1	119
4	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	3.2	94
5	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiology of Aging, 2012, 33, 629.e5-629.e18.	3.1	73
6	Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy, 2011, 42, 131-141.	2.1	65
7	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Human Mutation, 2009, 30, 1054-1061.	2.5	58
8	Mindfulness Training among Individuals with Parkinsonâ€™s Disease: Neurobehavioral Effects. Parkinson's Disease, 2015, 2015, 1-6.	1.1	58
9	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiology of Aging, 2011, 32, 548.e9-548.e18.	3.1	56
10	Global investigation and meta-analysis of the C9orf72 (G ₄ C ₂) _n repeat in Parkinson disease. Neurology, 2014, 83, 1906-1913.	1.1	56
11	Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. Parkinsonism and Related Disorders, 2011, 17, 135-138.	2.2	54
12	Mutated ATP10B increases Parkinsonâ€™s disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathologica, 2020, 139, 1001-1024.	7.7	46
13	Myoclonus and Cerebellar Ataxia Following COVIDâ€19. Movement Disorders Clinical Practice, 2020, 7, 974-976.	1.5	41
14	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinsonâ€™s disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Neuroscience Letters, 2016, 629, 160-164.	2.1	34
15	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
16	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology, 2015, 85, 1283-1292.	1.1	25
17	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. American Journal of Neurodegenerative Disease, 2012, 1, 160-7.	0.1	24
18	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 25.	5.2	23

#	Article	IF	Citations
19	Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population. Neurobiology of Aging, 2012, 33, 1844.e11-1844.e13.	3.1	21
20	REM sleep without atonia and the relation with Lewy body disease. Parkinsonism and Related Disorders, 2019, 67, 90-98.	2.2	21
21	Comprehensive Genetic and Mutation Analysis of Familial Dementia with Lewy Bodies Linked to 2q35-q36. Journal of Alzheimer's Disease, 2010, 20, 197-205.	2.6	20
22	Impulse control disorders in Parkinsonâ€™s disease: an overview from neurobiology to treatment. Journal of Neurology, 2015, 262, 7-20.	3.6	20
23	Nonâ€replication of association for six polymorphisms from metaâ€analysis of genomeâ€wide association studies of Parkinson's disease: Largeâ€scale collaborative study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 220-228.	1.7	16
24	GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. Neurobiology of Aging, 2011, 32, 308-312.	3.1	14
25	Alphaâ€synuclein repeat variants and survival in Parkinson's disease. Movement Disorders, 2014, 29, 1053-1057.	3.9	14
26	Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopaâ€responsive dystonia. Movement Disorders, 2012, 27, 1451-1456.	3.9	11
27	Polysomnographic phenotype of isolated REM sleep without atonia. Clinical Neurophysiology, 2020, 131, 2508-2515.	1.5	11
28	Spectrum of Movement Disorders in 18p Deletion Syndrome. Movement Disorders Clinical Practice, 2019, 6, 70-73.	1.5	10
29	Frequency and characteristic features of REM sleep without atonia. Clinical Neurophysiology, 2019, 130, 1825-1832.	1.5	9
30	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiology of Aging, 2017, 49, 217.e1-217.e4.	3.1	7
31	REM sleep without atonia and nocturnal body position in prediagnostic Parkinson's disease. Sleep Medicine, 2021, 84, 308-316.	1.6	6
32	Editorial: Prodromal Parkinson's Disease. Frontiers in Neurology, 2020, 11, 634490.	2.4	2
33	Impaired bed mobility in prediagnostic and de novo Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 47-52.	2.2	2
34	Impulsive-Compulsive Behaviours in Belgian-Flemish Parkinsonâ€™s Disease Patients: A Questionnaire-Based Study. Parkinson's Disease, 2019, 2019, 1-5.	1.1	1
35	Reply to: The Spectrum of Movement Disorders in 18p Deletion Syndrome. Movement Disorders Clinical Practice, 2019, 6, 731-732.	1.5	0
36	Cerebellar ataxia in progressive supranuclear palsy: a clinico-pathological case report. Acta Neurologica Belgica, 2021, 121, 599-602.	1.1	0

#	Article	IF	Citations
37	Physiotherapy may improve non-motor burden in people with Parkinson's disease. Parkinsonism and Related Disorders, 2020, 79, e54.	2.2	0